MA56520A - Construction de l'interleukine 12 recombinante et ses utilisations - Google Patents

Construction de l'interleukine 12 recombinante et ses utilisations

Info

Publication number
MA56520A
MA56520A MA056520A MA56520A MA56520A MA 56520 A MA56520 A MA 56520A MA 056520 A MA056520 A MA 056520A MA 56520 A MA56520 A MA 56520A MA 56520 A MA56520 A MA 56520A
Authority
MA
Morocco
Prior art keywords
construction
recombinant interleukin
interleukin
recombinant
Prior art date
Application number
MA056520A
Other languages
English (en)
Inventor
Daniel Boden
Pooter Dorien De
Helen Horton
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56520A publication Critical patent/MA56520A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056520A 2019-06-18 2020-06-18 Construction de l'interleukine 12 recombinante et ses utilisations MA56520A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19180939 2019-06-18

Publications (1)

Publication Number Publication Date
MA56520A true MA56520A (fr) 2022-04-27

Family

ID=67060253

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056520A MA56520A (fr) 2019-06-18 2020-06-18 Construction de l'interleukine 12 recombinante et ses utilisations

Country Status (4)

Country Link
US (1) US20250041386A1 (fr)
EP (1) EP3986915A1 (fr)
MA (1) MA56520A (fr)
WO (1) WO2020255014A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094330A (zh) 2017-07-03 2020-05-01 转矩医疗股份有限公司 编码免疫刺激融合分子的多核苷酸及其用途
WO2026020161A1 (fr) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Constructions d'il-12 activables et compositions et procédés associés

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (fr) 1904-11-07 1905-03-14 William Waid Paddock Filtre a pression
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
EP2428250A1 (fr) 1998-07-13 2012-03-14 Genetronics, Inc. Thérapie génique ciblant la peau et les muscles par champ magnétique pulsé
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
NZ585119A (en) 2004-03-08 2011-08-26 Ichor Medical Systems Inc Medical injector with surrounding electrical field generating penetrating electrodes
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
US20070025957A1 (en) * 2005-04-29 2007-02-01 Rosenblum Michael G Vascular targeting of ocular neovascularization
PT3524316T (pt) 2006-10-17 2024-11-29 Inovio Pharmaceuticals Inc Dispositivos de eletroporação para eletroporação de células em mamíferos
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
DK2817287T3 (da) 2012-02-24 2019-01-02 Arbutus Biopharma Corp Trialkyl kationisk lipid og metoder til anvendelse deraf
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
AU2016334401A1 (en) * 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
EP3397613A1 (fr) 2015-12-30 2018-11-07 Acuitas Therapeutics Inc. Lipides et formulations de nanoparticules de lipides pour la libération d'acides nucléiques
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents
WO2018191657A1 (fr) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipides pour administration d'agents actifs
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
US11421011B2 (en) * 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4501322A3 (fr) 2017-08-17 2025-04-16 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques
WO2019036030A1 (fr) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipides destinés à être utilisés dans des formulations de nanoparticules lipidiques

Also Published As

Publication number Publication date
EP3986915A1 (fr) 2022-04-27
WO2020255014A1 (fr) 2020-12-24
CA3141323A1 (fr) 2020-12-24
US20250041386A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
EP3902834A4 (fr) Compositions hétérodimeres d'anticorps à spécifiques et à tétravalents, et utilisations de celles-ci
EP3810171A4 (fr) Nouvelles protéines de fusion d'interleukine 15 (il-15) et utilisations de celles-ci
EP3762030A4 (fr) Anticorps anti-cd73 et utilisations associées
EP3810624A4 (fr) Médicaments bioactivables à base de cytokine et procédés d'utilisations associés
EP4085076C0 (fr) Anticorps se liant à bcma et leurs utilisations
EP3804389A4 (fr) Détermination et publication dynamiques d'amf de secours
MA52485A (fr) Combinaisons de variants d'anticorps et utilisations associées
EP3902837A4 (fr) Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation
EP3990498A4 (fr) Anticorps anti-cd24 et utilisations de celui-ci
EP3992209A4 (fr) Anticorps cldn18.2 et son utilisation
MY209489A (en) Antibody against human il-4ra and use thereof
MA54195A (fr) Conjugués d'interleukine 10 et leurs utilisations
EP3589660A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3813861A4 (fr) Polypeptides associés à l'héparine et leurs utilisations
EP3856192A4 (fr) Agents de dégradation ciblant l'alk et leurs utilisations thérapeutiques
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3601368A4 (fr) Constructions d'inducteur de présentation d'antigène tumoral et leurs utilisations
MA52289A (fr) Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
EP3755746A4 (fr) Polymère de silicone durcissable à l'humidité et ses utilisations
EP4408881A4 (fr) Anticorps spécifique de la protéine de spicule du sars-cov-2 et ses utilisations
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
EP3969526A4 (fr) Composition de revêtement et ses utilisations
IL308382A (en) New anti-CD276 antibodies and their uses
EP3966321A4 (fr) Ligases de protéine spécifiques à l'asx et leurs utilisations
IL290817A (en) Methods for production of human recombinant arginase 1 and uses thereof